TEKANO

Senolytic Therapeutics, originally founded as Tekano, is a preclinical-stage biotechnology company and a subsidiary of Life Biosciences. The company is dedicated to developing novel therapies that target cellular senescence, a fundamental mechanism of aging. By identifying and eliminating senescent cells—which accumulate with age and contribute to tissue dysfunction and chronic inflammation—Senolytic Therapeutics aims to treat a range of age-related diseases, including fibrosis and metabolic disorders. The company's approach utilizes a proprietary platform to discover senolytic and senomorphic agents, including small molecules and peptides, with a primary focus on the FOXO4-p53 signaling pathway.